Journal Article DKFZ-2025-00638

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Springer Nature [New York, NY]

Nature medicine 31(5), 1567-1577 () [10.1038/s41591-025-03562-5]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Molecular data integration plays a central role in central nervous system (CNS) tumor diagnostics but currently used assays pose limitations due to technical complexity, equipment and reagent costs, as well as lengthy turnaround times. We previously reported the development of Rapid-CNS2, an adaptive-sampling-based nanopore sequencing workflow. Here we comprehensively validated and further developed Rapid-CNS2 for intraoperative use. It now offers real-time methylation classification and DNA copy number information within a 30-min intraoperative window, followed by comprehensive molecular profiling within 24 h, covering the complete spectrum of diagnostically and therapeutically relevant information for the respective entity. We validated Rapid-CNS2 in a multicenter setting on 301 archival and prospective samples including 18 samples sequenced intraoperatively. To broaden the utility of methylation-based CNS tumor classification, we developed MNP-Flex, a platform-agnostic methylation classifier encompassing 184 classes. MNP-Flex achieved 99.6% accuracy for methylation families and 99.2% accuracy for methylation classes with clinically applicable thresholds across a global validation cohort of more than 78,000 frozen and formalin-fixed paraffin-embedded samples spanning five different technologies. Integration of these tools has the potential to advance CNS tumor diagnostics by providing broad access to rapid, actionable molecular insights crucial for personalized treatment strategies.

Classification:

Note: #EA:B300#LA:B300#LA:B062# / 2025 May;31(5):1567-1577

Contributing Institute(s):
  1. KKE Neuropathologie (B300)
  2. DKTK HD zentral (HD01)
  3. Künstl. Intelligenz in der Onkologie (B450)
  4. DKTK Koordinierungsstelle Berlin (BE01)
  5. DKTK Koordinierungsstelle Frankfurt (FM01)
  6. B067 Juniorgruppe Brain Tumor Translational Target (B067)
  7. B062 Pädiatrische Neuroonkologie (B062)
  8. KKE Neuroonkologie (B320)
  9. Pädiatrische Gliomforschung (B360)
Research Program(s):
  1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2025
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Nature ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 80 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2025-03-27, last modified 2025-05-22



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)